DOCSLIB.ORG

Vaccine Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

COVID-19: vaccine summary Vaccination data through Jun 2, 2021 as of Jun 3, 2021 at 12:05 AM Data in this report are provisional and subject to change. Data in this summary pertain to COVID-19 vaccines approved by the U.S. Food and Drug Administration and have been issued an Emergency Use Authorization (Janssen COVID-19 Vaccine, Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine). These data summarize the number of people who have received either their first dose or have completed the series for a COVID-19 vaccine. A person can only be counted in one category, first dose or series complete. For persons receiving Moderna or Pfizer vaccines, once they receive their second dose, they are moved from the first dose column to the series completed column. Because of this, the total first dose category may show a change from report to report not matching the total receiving their first dose from the previous day. Persons receiving Johnson & Johnson vaccines will always be counted in the series completed column. Series Total people COVID-19 doses for vaccinated persons in Florida Demographic summary First dose complete vaccinated Doses 17,967,048 Age group 2,004,239 8,393,060 10,397,299 People receiving one dose of a 1-dose series (Johnson & Johnson) or receiving only 12-14 years 91,161 410 91,571 one dose of a 2-dose series (Moderna, Pfizer) count once. Persons receiving both 15-24 years 255,486 519,348 774,834 doses of a 2-dose series count twice. 25-34 years 245,243 738,278 983,521 35-44 years 268,949 945,725 1,214,674 45-54 years 287,529 1,211,204 1,498,733 Current status of persons vaccinated for COVID-19 in Florida 55-64 years 315,642 1,673,943 1,989,585 Total people vaccinated 10,397,299 65-74 years 296,075 1,887,402 2,183,477 First dose 2,004,239 75-84 years 171,754 1,064,532 1,236,286 Series completed 8,393,060 85+ years 72,400 352,218 424,618 Completed 1-dose series 823,311 Race 2,004,239 8,393,060 10,397,299 Completed 2-dose series 7,569,749 White 1,212,293 5,614,265 6,826,558 First dose: current number of people who have only received their first dose of the Black 174,861 579,002 753,863 Moderna or Pfizer vaccine. American Indian/Alaskan 11,200 30,262 41,462 Series complete: current number of people who have received both Moderna or Pfizer vaccine doses or one Johnson & Johnson dose and are considered fully Other 266,307 925,520 1,191,827 immunized. Unknown 339,578 1,244,011 1,583,589 Other race includes Asian, native Hawaiian/Pacific Islander, or other. Ethnicity 2,004,239 8,393,060 10,397,299 Hispanic 496,664 1,397,586 1,894,250 Non-Hispanic 820,510 4,283,636 5,104,146 Unknown 687,065 2,711,838 3,398,903 Gender 2,004,239 8,393,060 10,397,299 Female 1,056,886 4,586,173 5,643,059 Male 936,991 3,794,071 4,731,062 Unknown 10,362 12,816 23,178 COVID-19 doses administered for the past 2 weeks 90,551 84,929 79,392 72,716 80,160 79,651 75,149 78,431 58,691 62,870 41,179 40,923 15,836 22,490 5/20 5/21 5/22 5/23 5/24 5/25 5/26 5/27 5/28 5/29 5/30 5/31 6/1 6/2 Date dose administered (12:00 am to 11:59 pm) Persons vaccinated for COVID-19 for the past 2 weeks Number of persons who received their first dose of a two-dose series of the COVID-19 vaccine 36,183 37,687 37,180 33,800 34,316 34,242 31,501 32,050 27,570 24,471 17,927 18,961 5,991 8,084 5/20 5/21 5/22 5/23 5/24 5/25 5/26 5/27 5/28 5/29 5/30 5/31 6/1 6/2 Date dose administered (12:00 am to 11:59 pm) Number of persons who completed the COVID-19 vaccine series 52,864 45,844 47,749 45,409 46,381 43,209 38,916 43,648 38,399 31,121 23,252 21,962 9,845 14,406 5/20 5/21 5/22 5/23 5/24 5/25 5/26 5/27 5/28 5/29 5/30 5/31 6/1 6/2 Date dose administered (12:00 am to 11:59 pm) COVID-19: vaccine summary Vaccination data through Jun 2, 2021 as of Jun 3, 2021 at 12:05 AM Data in this report are provisional and subject to change. This table summarizes the number of people who have received either their first dose or have completed the series for a COVID-19 vaccine. A person can only be counted in one category, first dose or series complete. Persons receiving Johnson & Johnson vaccines will always be counted in the series completed column (see previous page for additional information). Yesterday (Jun 2) Cumulative Series Total people Series Total people County of residence First dose First dose complete vaccinated complete vaccinated Alachua 69 64 133 17,745 113,045 130,790 Baker 8 12 20 1,527 4,971 6,498 Bay 40 89 129 9,499 48,315 57,814 Bradford 6 4 10 3,084 6,473 9,557 Brevard 107 150 257 43,084 234,527 277,611 Broward 1,028 1,864 2,892 219,369 787,393 1,006,762 Calhoun 0 8 8 475 3,120 3,595 Charlotte 37 70 107 22,794 87,150 109,944 Citrus 44 93 137 9,349 56,701 66,050 Clay 33 67 100 11,915 60,623 72,538 Collier 95 181 276 34,023 178,039 212,062 Columbia 14 28 42 2,471 15,938 18,409 Dade 1,616 3,192 4,808 358,007 1,212,839 1,570,846 Desoto 7 13 20 3,250 10,541 13,791 Dixie 8 21 29 945 3,257 4,202 Duval 293 496 789 63,866 308,107 371,973 Escambia 49 67 116 18,783 90,714 109,497 Flagler 17 47 64 8,605 49,323 57,928 Franklin 2 2 4 489 3,916 4,405 Gadsden 57 46 103 2,735 15,894 18,629 Gilchrist 2 12 14 618 3,997 4,615 Glades 4 6 10 620 4,152 4,772 Gulf 3 5 8 738 4,023 4,761 Hamilton 12 16 28 391 3,014 3,405 Hardee 16 67 83 1,632 5,938 7,570 Hendry 55 41 96 2,431 10,455 12,886 Hernando 49 81 130 12,988 64,532 77,520 Highlands 38 61 99 11,539 34,765 46,304 Hillsborough 716 928 1,644 146,361 487,668 634,029 Holmes 5 17 22 524 3,606 4,130 Indian River 31 49 80 18,989 70,426 89,415 Jackson 14 13 27 2,170 12,003 14,173 Jefferson 1 6 7 639 4,949 5,588 Lafayette 1 3 4 365 2,105 2,470 Lake 96 166 262 27,038 149,883 176,921 Lee 209 505 714 60,985 306,374 367,359 Leon 103 178 281 19,803 105,445 125,248 Levy 12 14 26 1,898 11,475 13,373 Liberty 1 8 9 318 1,843 2,161 Madison 0 2 2 966 4,970 5,936 Manatee 101 112 213 32,642 156,445 189,087 Marion 78 118 196 22,936 132,380 155,316 Martin 21 72 93 13,968 68,089 82,057 Monroe 14 10 24 9,197 33,892 43,089 Nassau 10 41 51 3,879 32,661 36,540 Okaloosa 82 185 267 11,046 58,207 69,253 Okeechobee 8 15 23 1,828 10,844 12,672 Orange 689 1,050 1,739 123,289 525,493 648,782 Osceola 290 423 713 36,835 140,528 177,363 Out-Of-State 300 211 511 90,634 163,795 254,429 Palm Beach 439 1,091 1,530 136,969 612,147 749,116 Pasco 139 241 380 43,316 196,109 239,425 Pinellas 193 404 597 69,265 407,126 476,391 Polk 225 452 677 57,167 222,561 279,728 Putnam 13 30 43 4,902 16,980 21,882 Santa Rosa 30 77 107 11,336 51,954 63,290 Sarasota 80 210 290 47,175 211,972 259,147 Seminole 96 164 260 33,835 190,159 223,994 St. Johns 43 66 109 15,854 121,926 137,780 St. Lucie 118 148 266 30,265 114,380 144,645 Sumter 18 76 94 9,366 77,889 87,255 Suwannee 12 12 24 1,709 9,318 11,027 Taylor 5 24 29 1,256 5,004 6,260 Union 4 2 6 669 2,902 3,571 Unknown 12 165 177 3,521 9,361 12,882 Volusia 96 241 337 39,792 201,502 241,294 Wakulla 4 12 16 2,572 9,061 11,633 Walton 57 36 93 5,123 22,414 27,537 Washington 9 26 35 865 5,452 6,317 Total 8,084 14,406 22,490 2,004,239 8,393,060 10,397,299.
Recommended publications
  • Florida, California and Texas Dominate Future Population Growth, While Michigan's Slow Growth Moves It out of the Top 10 Three

    Florida, California and Texas Dominate Future Population Growth, While Michigan's Slow Growth Moves It out of the Top 10 Three

    Florida, California and Texas Dominate Future Population Growth, While Michigan’s Slow Growth Moves It Out of the Top 10 Three states — Florida, California and Texas — are projected to account for nearly one- half (46 percent) of the total U.S. population growth of 82 million persons between 2000 and 2030, according to Census Bureau state population projections released today. Florida, now the fourth most populous state, would edge past New York into third place in total population by 2011; California and Texas would continue to rank first and second, respectively, in 2030. Rounding out the top 5 gainers are Arizona and North Carolina. Top five fastest-growing states between 2000 and 2030 would be Nevada (114 percent), Arizona (109 percent), Florida (80 percent), Texas (60 percent) and Utah (56 percent). Only West Virginia, North Dakota and the District of Columbia are projected to lose population over this period. (See Table 1) Michigan is projected to gain 755,728 residents over the 30-year period. This increase places it 21st among the 50 States and District of Columbia. The 7.6 percent population increase that this represents ranks 40th. Further analysis of Michigan’s projections shows that the Census Bureau expects a slowing of growth over the 30-year period, culminating in losses between 2025 and 20301. The 5-year population change rates projected for Michigan, starting with 2000-2005 are: 2.7%; 2.2%; 1.6%; 0.9%; 0.2%; and –0.2%. The results of these changes on Michigan’s ranking among the States are shown in Table 2.
  • Vaccination Certificate Information Version: 21 July 2021

    Vaccination Certificate Information Version: 21 July 2021

    معلومات عن شهادة التطعيم، بالعربية 中文疫苗接种凭证信息 Informations sur le certificat de vaccination en FRANÇAIS Информация о сертификате вакцинации на РУССКОМ ЯЗЫКЕ Información sobre el Certificado de Vacunación en ESPAÑOL UN SYSTEM-WIDE COVID-19 VACCINATION PROGRAMME VACCINATION CERTIFICATE INFORMATION VERSION: 21 JULY 2021 ABOUT THE UN SYSTEM-WIDE COVID-19 VACCINATION PROGRAMME The UN is committed to ensuring the protection of its personnel. Tasked by the Secretary-General, the Department of Operational Support (DOS) is leading a coordinated, UN-system-wide effort to ensure the availability of vaccine to UN personnel, their dependents and implementing partners. The roll-out of the UN System-wide COVID-19 Vaccination Programme (the “Programme”) for UN personnel will provide a significant boost to the ability of personnel to stay and deliver on the Organization's mandates, to support beneficiaries in the communities they serve, and to contribute to our on-going work to recover better together from the pandemic. Information about the Programme is available at: https://www.un.org/en/coronavirus/vaccination ABOUT THE VACCINATION CERTIFICATE Upon administration of the requisite vaccine dosage, a certificate of vaccination is generated through the Programme’s registration platform (the “Platform”). The certificate generated by the Platform uses a standardized format, similar to the one used by the WHO in its “International Certificate of Vaccination or Prophylaxis” (Yellow) vaccination booklet. Note: This certificate may not dispense with travel restrictions put in place by the country(ies) of destination. As the nature of the pandemic continues to rapidly evolve, it is highly advisable to check the latest travel regulations.
  • Global Dynamics of a Vaccination Model for Infectious Diseases with Asymptomatic Carriers

    Global Dynamics of a Vaccination Model for Infectious Diseases with Asymptomatic Carriers

    MATHEMATICAL BIOSCIENCES doi:10.3934/mbe.2016019 AND ENGINEERING Volume 13, Number 4, August 2016 pp. 813{840 GLOBAL DYNAMICS OF A VACCINATION MODEL FOR INFECTIOUS DISEASES WITH ASYMPTOMATIC CARRIERS Martin Luther Mann Manyombe1;2 and Joseph Mbang1;2 Department of Mathematics, Faculty of Science University of Yaounde 1, P.O. Box 812 Yaounde, Cameroon 1;2;3; Jean Lubuma and Berge Tsanou ∗ Department of Mathematics and Applied Mathematics University of Pretoria, Pretoria 0002, South Africa (Communicated by Abba Gumel) Abstract. In this paper, an epidemic model is investigated for infectious dis- eases that can be transmitted through both the infectious individuals and the asymptomatic carriers (i.e., infected individuals who are contagious but do not show any disease symptoms). We propose a dose-structured vaccination model with multiple transmission pathways. Based on the range of the explic- itly computed basic reproduction number, we prove the global stability of the disease-free when this threshold number is less or equal to the unity. Moreover, whenever it is greater than one, the existence of the unique endemic equilibrium is shown and its global stability is established for the case where the changes of displaying the disease symptoms are independent of the vulnerable classes. Further, the model is shown to exhibit a transcritical bifurcation with the unit basic reproduction number being the bifurcation parameter. The impacts of the asymptomatic carriers and the effectiveness of vaccination on the disease transmission are discussed through through the local and the global sensitivity analyses of the basic reproduction number. Finally, a case study of hepatitis B virus disease (HBV) is considered, with the numerical simulations presented to support the analytical results.
  • The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given

    The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given

    Hepatitis B Vaccine Protect Yourself and Those You Love What is Hepatitis B? Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV), which attacks liver cells and can lead to liver failure, cirrhosis (scarring), or liver cancer later in life. The virus is transmitted through direct contact with infected blood and bodily fluids, and from an infected woman to her newborn at birth. Is there a safe vaccine for hepatitis B? YES! The good news is that there is a safe and effective vaccine for hepatitis B. The vaccine is a series, typically given as three shots over a six-month period that will provide a lifetime of protection. You cannot get hepatitis B from the vaccine – there is no human blood or live virus in the vaccine. The hepatitis B vaccine is the most widely used vaccine in the world, with over 1 billion doses given. The hepatitis B vaccine is the first "anti-cancer" vaccine because it can help prevent liver cancer! Who should be vaccinated against hepatitis B? The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend the hepatitis B vaccine for all newborns and children up to 18 years of age, and all high-risk adults. All infants should receive the first dose of the vaccine in the delivery room or in the first 24 hours of life, preferably within 12 hours. (CDC recommends the first dose within 12 hours vs. the WHO recommendation of 24 hours.) The HBV vaccine is recommended to anyone who is at high risk of infection.
  • The English Invasion of Spanish Florida, 1700-1706

    The English Invasion of Spanish Florida, 1700-1706

    Florida Historical Quarterly Volume 41 Number 1 Florida Historical Quarterly, Vol 41, Article 7 Issue 1 1962 The English Invasion of Spanish Florida, 1700-1706 Charles W. Arnade Part of the American Studies Commons, and the United States History Commons Find similar works at: https://stars.library.ucf.edu/fhq University of Central Florida Libraries http://library.ucf.edu This Article is brought to you for free and open access by STARS. It has been accepted for inclusion in Florida Historical Quarterly by an authorized editor of STARS. For more information, please contact [email protected]. Recommended Citation Arnade, Charles W. (1962) "The English Invasion of Spanish Florida, 1700-1706," Florida Historical Quarterly: Vol. 41 : No. 1 , Article 7. Available at: https://stars.library.ucf.edu/fhq/vol41/iss1/7 Arnade: The English Invasion of Spanish Florida, 1700-1706 THE ENGLISH INVASION OF SPANISH FLORIDA, 1700-1706 by CHARLES W. ARNADE HOUGH FLORIDA had been discovered by Ponce de Leon in T 1513, not until 1565 did it become a Spanish province in fact. In that year Pedro Menendez de Aviles was able to establish a permanent capital which he called St. Augustine. Menendez and successive executives had plans to make St. Augustine a thriving metropolis ruling over a vast Spanish colony that might possibly be elevated to a viceroyalty. Nothing of this sort happened. By 1599 Florida was in desperate straits: Indians had rebelled and butchered the Franciscan missionaries, fire and flood had made life in St. Augustine miserable, English pirates of such fame as Drake had ransacked the town, local jealousies made life unpleasant.
  • COMPLIANCE AGREEMENT / MAMEY SAPOTE NICOLE "NIKKI" FRIED COMMISSIONER Section 581.031(26), F.S

    COMPLIANCE AGREEMENT / MAMEY SAPOTE NICOLE "NIKKI" FRIED COMMISSIONER Section 581.031(26), F.S

    Florida Department of Agriculture and Consumer Services Division of Plant Industry COMPLIANCE AGREEMENT / MAMEY SAPOTE NICOLE "NIKKI" FRIED COMMISSIONER Section 581.031(26), F.S. 1911 S.W. 34th Street/P. O. Box 147100, Gainesville, FL 32608 / (352) 395-4700 1. NAME AND MAILING ADDRESS OF PERSON OR FIRM 2. LOCATION 3. REGULATED ARTICLE(S): Fruit of mamey sapote (Pouteria sapota) 4. APPLICABLE STATE QUARANTINE(S) OR REGULATIONS: California Caribbean fruit fly exterior quarantine CCR3252 I / we agree to handle, pack, process, and move regulated articles in accordance with applicable plant quarantines; use all permits and certificates in accordance with instructions; maintain and offer for inspection such records as may be required; and abide by the following stipulations: In order to ensure compliance with California’s Caribbean fruit fly exterior quarantine (CCR 3252), the following conditions will be adhered to: 1. All mamey fruit (Pouteria sapota) shipped to California will be obtained from Florida producers, inspected for pests by the shipper, certified as Florida grown by the department, and then packed and shipped in new boxes from Florida. 2. There will be no co-mingling with mamey fruit (Pouteria sapota) not of Florida origin, or any other fruit of any kind not certified for shipment to California. All mamey fruit destined for California will be kept safeguarded from pests while in Florida storage and during shipment. 3. Each shipment will be accompanied by a tag or stamp imprint authorized by the department signifying that the fruit is Florida grown (i.e., was harvested solely from trees producing in Florida). 4.
  • State Abbreviations

    State Abbreviations

    State Abbreviations Postal Abbreviations for States/Territories On July 1, 1963, the Post Office Department introduced the five-digit ZIP Code. At the time, 10/1963– 1831 1874 1943 6/1963 present most addressing equipment could accommodate only 23 characters (including spaces) in the Alabama Al. Ala. Ala. ALA AL Alaska -- Alaska Alaska ALSK AK bottom line of the address. To make room for Arizona -- Ariz. Ariz. ARIZ AZ the ZIP Code, state names needed to be Arkansas Ar. T. Ark. Ark. ARK AR abbreviated. The Department provided an initial California -- Cal. Calif. CALIF CA list of abbreviations in June 1963, but many had Colorado -- Colo. Colo. COL CO three or four letters, which was still too long. In Connecticut Ct. Conn. Conn. CONN CT Delaware De. Del. Del. DEL DE October 1963, the Department settled on the District of D. C. D. C. D. C. DC DC current two-letter abbreviations. Since that time, Columbia only one change has been made: in 1969, at the Florida Fl. T. Fla. Fla. FLA FL request of the Canadian postal administration, Georgia Ga. Ga. Ga. GA GA Hawaii -- -- Hawaii HAW HI the abbreviation for Nebraska, originally NB, Idaho -- Idaho Idaho IDA ID was changed to NE, to avoid confusion with Illinois Il. Ill. Ill. ILL IL New Brunswick in Canada. Indiana Ia. Ind. Ind. IND IN Iowa -- Iowa Iowa IOWA IA Kansas -- Kans. Kans. KANS KS A list of state abbreviations since 1831 is Kentucky Ky. Ky. Ky. KY KY provided at right. A more complete list of current Louisiana La. La.
  • Vaccine Hesitancy

    Vaccine Hesitancy

    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
  • AAMC Standardized Immunization Form

    AAMC Standardized Immunization Form

    AAMC Standardized Immunization Form Middle Last Name: First Name: Initial: DOB: Street Address: Medical School: City: Cell Phone: State: Primary Email: ZIP Code: AAMC ID: MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option. Copy Note: a 3rd dose of MMR vaccine may be advised during regional outbreaks of measles or mumps if original MMR vaccination was received in childhood. Attached Option1 Vaccine Date MMR Dose #1 MMR -2 doses of MMR vaccine MMR Dose #2 Option 2 Vaccine or Test Date Measles Vaccine Dose #1 Serology Results Measles Qualitative -2 doses of vaccine or Measles Vaccine Dose #2 Titer Results: Positive Negative positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Mumps Vaccine Dose #1 Serology Results Mumps Qualitative -2 doses of vaccine or Mumps Vaccine Dose #2 Titer Results: Positive Negative positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Serology Results Rubella Qualitative Positive Negative -1 dose of vaccine or Rubella Vaccine Titer Results: positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Tetanus-diphtheria-pertussis – 1 dose of adult Tdap; if last Tdap is more than 10 years old, provide date of last Td or Tdap booster Tdap Vaccine (Adacel, Boostrix, etc) Td Vaccine or Tdap Vaccine booster (if more than 10 years since last Tdap) Varicella (Chicken Pox) - 2 doses of varicella vaccine or positive serology Varicella Vaccine #1 Serology Results Qualitative Varicella Vaccine #2 Titer Results: Positive Negative Serologic Immunity (IgG antibody titer) Quantitative Titer Results: _____ IU/ml Influenza Vaccine --1 dose annually each fall Date Flu Vaccine © 2020 AAMC.
  • Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC)

    Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC)

    AAMC Standardized Immunization Form 2020 Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC) 1. What are the hepatitis B vaccines licensed for use in the United States? Three single-antigen vaccines and two combination vaccines are currently licensed in the United States. Single-antigen hepatitis B vaccines: • ENGERIX-B® • RECOMBIVAX HB® • HEPLISAV-B™ Combination vaccines: • PEDIARIX®: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years. • TWINRIX®: Combined Hepatitis A and hepatitis B vaccine. Recommended for people aged ≥18 years who are at increased risk for both HAV and HBV infections. 2. What are the recommended schedules for hepatitis B vaccination? The vaccination schedule most often used for children and adults is three doses given at 0, 1, and 6 months. Alternate schedules have been approved for certain vaccines and/or populations. A new formulation, Heplisav-B (HepB-CpG), is approved to be given as two doses one month apart. 3. If there is an interruption between doses of hepatitis B vaccine, does the vaccine series need to be restarted? No. The series does not need to be restarted but the following should be considered: • If the vaccine series was interrupted after the first dose, the second dose should be administered as soon as possible. • The second and third doses should be separated by an interval of at least 8 weeks. • If only the third dose is delayed, it should be administered as soon as possible. 4. Is it harmful to administer an extra dose of hepatitis B vaccine or to repeat the entire vaccine series if documentation of the vaccination history is unavailable or the serology test is negative? No, administering extra doses of single-antigen hepatitis B vaccine is not harmful.
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments

    Statements Contained in This Release As the Result of New Information Or Future Events Or Developments

    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
  • COVID-19 Vaccines Frequently Asked Questions

    COVID-19 Vaccines Frequently Asked Questions

    Page 1 of 12 COVID-19 Vaccines 2020a Frequently Asked Questions Michigan.gov/Coronavirus The information in this document will change frequently as we learn more about COVID-19 vaccines. There is a lot we are learning as the pandemic and COVID-19 vaccines evolve. The approach in Michigan will adapt as we learn more. September 29, 2021. Quick Links What’s new | Why COVID-19 vaccination is important | Booster and additional doses | What to expect when you get vaccinated | Safety of the vaccine | Vaccine distribution/prioritization | Additional vaccine information | Protecting your privacy | Where can I get more information? What’s new − Pfizer booster doses recommended for some people to boost waning immunity six months after completing the Pfizer vaccine. Why COVID-19 vaccination is important − If you are fully vaccinated, you don’t have to quarantine after being exposed to COVID-19, as long as you don’t have symptoms. This means missing less work, school, sports and other activities. − COVID-19 vaccination is the safest way to build protection. COVID-19 is still a threat, especially to people who are unvaccinated. Some people who get COVID-19 can become severely ill, which could result in hospitalization, and some people have ongoing health problems several weeks or even longer after getting infected. Even people who did not have symptoms when they were infected can have these ongoing health problems. − After you are fully vaccinated for COVID-19, you can resume many activities that you did before the pandemic. CDC recommends that fully vaccinated people wear a mask in public indoor settings if they are in an area of substantial or high transmission.